KRAS and cancer: AURKA was shown to be the most promising combination with ARS1620 (KRAS-Inhibitor) therapy option in a previous study that was presented by Peindl et al. [40] and AURKA is often discussed in the literature as promising drug-target point in cancer therapy [15], [52], [63].